Skip to main content
SpringerLink
Log in

Cyproterone Acetate (CPA)

  • Chapter
  • First Online:
Androgenetic Alopecia From A to Z

  • 575 Accesses

Abstract

Cyproterone acetate (CPA) is a very potent synthetic analog of progesterone, classified as a progestin. It was discovered in 1962 by the German company Schering. CPA was developed from 17α-hydroxyprogesterone, and it is estimated to be approximately 1200 times more potent as an antiandrogen than 17α-acetoxyprogesterone [1]. CPA is marketed under the brand name Androcur® since 1964. It is currently used widely in most countries, representing the first specific antiandrogen of clinical interest, with the notable major exceptions of the USA and Japan. In the USA, CPA is available only as an orphan drug for the treatment of hirsutism since the FDA has not approved it yet.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Neumann F. the antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol. 1994;102(1):1–32.

    CAS  PubMed  Google Scholar 

  2. Krause W. Teratogenic damages of the male genital organs. Fortschr Med. 1976;94(30):1673–5.

    CAS  PubMed  Google Scholar 

  3. Erdmann D, Schindler EM, Schindler AE. Ovarian suppression with Diane 35/50. Geburtshilfe Frauenheilkd. 1994;54:627–33.

    CAS  PubMed  Google Scholar 

  4. Diamanti-Kandarakis E, Tolis G, Duleba AJ. Androgens and therapeutic aspects of antiandrogens in women. J Soc Gynecol Investig. 1995;2(4):577–92.

    CAS  PubMed  Google Scholar 

  5. Neumann F, Berswordt-Wallrabe RVO, Elger W, Steinbeck H, Hahn JD, Kramer M. Aspects of androgen-dependent events as studied by antiandrogens. Recent Prog Horm Res. 1970;26:337–410.

    CAS  PubMed  Google Scholar 

  6. Vermorken AJ, Goos CM, Sultan C, Vermeesch-Markslag AM, Dijkstra AC. Studies on the local activity of antiandrogens at the molecular and histological level. Mol Biol Rep. 1986;11(2):99–105.

    CAS  PubMed  Google Scholar 

  7. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223–30.

    CAS  PubMed  Google Scholar 

  8. Mowszowicz I, Wright F, Vincens M, Rigaud C, Nahoul K, Mavier P, Guillemant S, Kuttenn F, Mauvais-Jarvis P. Androgen metabolism in hirsute patients treated with cyproterone acetate. J Steroid Biochem. 1984;20(3):757–61.

    CAS  PubMed  Google Scholar 

  9. Humpel M, Wendt H, Schulze PE, Dogs G, Weiss C, Speck U. Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women. Contraception. 1977;15(5):579–88.

    CAS  PubMed  Google Scholar 

  10. Huber J, Zeillinger R, Schmidt J, Tauber U, Kuhnz W, Spona J. Pharmacokinetics of cyproterone acetate and its main metabolite 15 beta-hydroxy-cyproterone acetate in young healthy women. Int J Clin Pharmacol Ther Toxicol. 1988;26:555–61.

    CAS  PubMed  Google Scholar 

  11. Hammerstein J, Meckies J, Leo-Rossberg I, Moltz L, Zielske F. Use of cyproterone acetate (CPA) in the treatment of acne, hirsutism and virilism. J Steroid Biochem. 1975;6(6):827–36.

    CAS  PubMed  Google Scholar 

  12. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertil Steril. 2002;77(5):919–27.

    PubMed  Google Scholar 

  13. Neumann F. Pharmacological basis for clinical use of antiandrogens. J Steroid Biochem. 1983;19(1A):391–402.

    CAS  PubMed  Google Scholar 

  14. Camacho-Martínez FM. Hair loss in women. Semin Cutan Med Surg. 2009;28(1):19–32.

    PubMed  Google Scholar 

  15. Pugeat M, Nicolas MH, Dechaud H, Elmidani M. Combination of cyproterone acetate and natural estrogens in the treatment of Hirsutism. J Gynecol Obstet Biol Reprod (Paris). 1991;20(8):1057–62.

    CAS  PubMed  Google Scholar 

  16. Olsen EA, Messenger AG, Shapiro J, Bergfeld WF, Hordinsky MK, Roberts JL, Stough D, Washenik K, Whiting DA. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301–11.

    PubMed  Google Scholar 

  17. Hammerstein J, Cupceancu B. Management of hirsutism using cyproterone acetate. Dtsch Med Wochenschr. 1969;94(16):829–34.

    CAS  PubMed  Google Scholar 

  18. Camacho F. Tratamiento del hirsutismo. Actas Dermosifiliogr. 2006;97(Suppl. 1):33–44.

    Google Scholar 

  19. van Zuuren EJ, Fedorowicz Z, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2016;26(5):CD007628.

    Google Scholar 

  20. Ekoe JM, Burckhardt P, Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica. 1980;160(6):398–404.

    CAS  PubMed  Google Scholar 

  21. Dawber RP, Sonnex T, Ralfs I. Oral antiandrogen treatment of common baldness in women. Br J Dermatol. 1982;107(Suppl):20–1.

    Google Scholar 

  22. Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989;69(5):395–8.

    CAS  PubMed  Google Scholar 

  23. Mortimer CH, Rushton H, James KC. Effective medical treatment of common baldness in women. Clin Exp Dermatol. 1984;9(4):342–50.

    CAS  PubMed  Google Scholar 

  24. Rushton DH, Ramsay ID. The importance of adequate serum ferritin levels during oral cyproterone acetate and ethinyl oestradiol treatment of diffuse androgen-dependent alopecia in women. Clin Endocrinol (Oxf). 1992;36(4):421–7.

    CAS  PubMed  Google Scholar 

  25. Minozzi M, Unfer V, Constabile L. Alopecia androgenetica in post–menopausa. G Ital Ostet e Ginecol. 1997;19(6):341–4.

    Google Scholar 

  26. Carmina E, Lobo RA. Treatment of hyperandrogenic alopecia in women. Fertil Steril. 2003;79(1):91–5.

    PubMed  Google Scholar 

  27. Brzezinska-Wcislo L. Assessment of efficacy of Diane-35 in androgenetic feminine alopecia. Wiad Lek. 2003;56:202–5.

    PubMed  Google Scholar 

  28. Vexiau P, Chaspoux C, Boudou P, Fiet J, Jouanique C, Hardy N, Reygagne P. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002;146(6):992–9.

    CAS  PubMed  Google Scholar 

  29. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005;152(3):466–73.

    CAS  PubMed  Google Scholar 

  30. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Gomez F. Androgen dependence of hirsutism, acne, and alopecia in women: retrospective analysis of 228 patients investigated for hyperandrogenism. Medicine (Baltimore). 2009;88(1):32–45.

    CAS  PubMed  Google Scholar 

  31. Kapadia N, Borhany T, Khalid G, et al. Systemic cyproterone acetate and 5% minoxidil topical in the treatment of female pattern hair loss. J Pak Assoc Dermatol. 2009;19:216–9.

    Google Scholar 

  32. Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189–99.

    PubMed  PubMed Central  Google Scholar 

  33. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men—short version. J Eur Acad Dermatol Venereol. 2018;32(1):11–22.

    CAS  PubMed  Google Scholar 

  34. Ebling FJ, Randall VA, Skinner J. Local suppression of sebum secretion in rats by topical cyproterone acetate in ethanol. J Invest Dermatol. 1981;77(6):458–63.

    CAS  PubMed  Google Scholar 

  35. Burton JL, Pye RJ, Harris JI. Effect of 1% cyproterone acetate in cetomacrogol cream BPC (formula A) on sebum excretion rate in patients with acne. Br J Dermatol. 1976;95(4):427–8.

    CAS  PubMed  Google Scholar 

  36. Lyons F, Shuster S. Indirect evidence that the action of cyproterone acetate on the skin is due to a metabolite. Clin Endocrinol (Oxf). 1983;19(1):53–5.

    CAS  PubMed  Google Scholar 

  37. Ekerdt R, Opitz D, Hübner H, Pätzold C, Töpert M. Percutaneous absorption of topically-applied antiandrogens: an assessment with three independent methods. Br J Dermatol. 1986;115(Suppl. 31):36–40.

    PubMed  Google Scholar 

  38. Gruber DM, Sator MO, Joura EA, Kokoschka EM, Heinze G, Huber JC. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. Arch Dermatol. 1998;134(4):459–63.

    CAS  PubMed  Google Scholar 

  39. Ghasemiyeh P, Azadi A, Daneshamouz S, Heidari R, Azarpira N, Mohammadi-Samani S. Cyproterone acetate-loaded nanostructured lipid carriers: effect of particle size on skin penetration and follicular targeting. Pharm Dev Technol. 2019;24(7):812–23.

    CAS  PubMed  Google Scholar 

  40. Camacho F. Hypertrichosis and hirsutism. In: Bolognia J, Jorizzo JL, Rapini RP, editors. Dermatology. 2nd ed. London: Mosby Ed; 2008. p. 1007–18.

    Google Scholar 

  41. van Wayjen RG, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103(4):241–51.

    PubMed  Google Scholar 

  42. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–9.

    CAS  PubMed  Google Scholar 

  43. Diamanti-Kandarakis E. Current aspects of antiandrogen therapy in women. Curr Pharm Des. 1999;5(9):707–23.

    CAS  PubMed  Google Scholar 

  44. Appelt H, Strauss B. Effects of antiandrogen treatment on the sexuality of women with hyperandrogenism. Psychother Psychosom. 1984;42(1–4):177–81.

    CAS  PubMed  Google Scholar 

  45. Adamopoulos DA, Kampyli S, Georgiacodis F, Kapolla N, Abrahamian-Michalakis A. Effects of antiandrogen-estrogen treatment on sexual and endocrine parameters in hirsute women. Arch Sex Behav. 1988;17(5):421–9.

    CAS  PubMed  Google Scholar 

  46. Heinemann LAJ, Will-Shahab L. Active surveillance study on patients treated with CPA long-term: the SEHOST project. Berlin: Research Report ZEG; 1995.

    Google Scholar 

  47. Wiegratz I, Stahlberg S, et al. Effects of combined oral contraceptive ethinylestradiol (30 microg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm Metab Res. 2010;42(5):358–63.

    CAS  PubMed  Google Scholar 

  48. Ramsay ID, Rushton DH. Reduced serum vitamin B12 levels during oral cyproterone-acetate and ethinyl-oestradiol therapy in women with diffuse androgen-dependent alopecia. Clin Exp Dermatol. 1990;15(4):277–81.

    CAS  PubMed  Google Scholar 

  49. Olsen EA. Female pattern hair loss. J Am Acad Dermatol. 2001;45(3 Suppl):S70–80.

    CAS  PubMed  Google Scholar 

  50. Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol. 1991;98(2):71–80.

    CAS  PubMed  Google Scholar 

  51. Moltz L, Neumann F, Hammerstein J. Modification of fertility of the male by antiandrogens. Gynakologe. 1980;13(1):18–32.

    CAS  PubMed  Google Scholar 

  52. Levesque H, Trivalle C, Manchon ND, Vinel JP, Moore N, Hemet J, Courtois H, Bercoff E, Bourreille J. Fulminant hepatitis due to cyproterone acetate. Lancet. 1989;1(8631):215–6.

    CAS  PubMed  Google Scholar 

  53. Rudiger T, Beckmann J, Queisser W. Hepatocellular carcinoma after treatment with cyproterone acetate combined with ethinyloestradiol. Lancet. 1995;345(8947):452–3.

    CAS  PubMed  Google Scholar 

  54. Vermorken AJ. Reversal of androgenic alopecia by minoxidil: Lack of effect of simultaneously administered intermediate doses of cyproterone acetate. Acta Derm Venereol. 1983;63(3):268–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Athens, Attiki, Greece

    Konstantinos Anastassakis

Authors
  1. Konstantinos Anastassakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Anastassakis, K. (2022). Cyproterone Acetate (CPA). In: Androgenetic Alopecia From A to Z . Springer, Cham. https://doi.org/10.1007/978-3-031-08057-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-08057-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-08056-2

  • Online ISBN: 978-3-031-08057-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation